Cart summary

You have no items in your shopping cart.

FXR agonist 12

SKU: orb2944390

Description

FXR agonist12 (Compound C7) is an orally active FXR agonist. It downregulates bile acid synthesis-related genes and upregulates bile acid transport-related genes in HepG2 cells. FXR agonist12 alleviates ANIT-induced cholestasis and reduces liver damage and fibrosis in a mouse model of NASH.

Images & Validation

Key Properties

CAS Number1831862-88-4
MW404.626
FormulaC26H44O3
SMILESC[C@@]12[C@@]3([C@]([C@]4([C@](C)(CC3)[C@@]([C@@H](CCC(O)=O)C)(CC4)[H])[H])([C@H](O)[C@H](CC)[C@@]1(CCCC2)[H])[H])[H]
TargetFXR

Storage & Handling

Storage-20°C
DisclaimerFor research use only

Similar Products

  • Ferolin [orb2943077]

    39380-12-6

    358.471

    C22H30O4

    10 mg, 50 mg
  • Altenusin [orb1218182]

    >98% (HPLC)

    31186-12-6

    290.3

    C15H14O6

    5 mg, 50 mg, 100 mg, 10 mg, 25 mg, 1 g, 500 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

FXR agonist 12 (orb2944390)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%